However, in adult normal mice, an antisense oligonucleotide (ASO)-mediated inhibition of miR-122 decreased plasma cholesterol levels, increased hepatic fatty acid oxidation, and decreased hepatic fatty acid and cholesterol synthesis rates, and in a diet-induced obesity model, the ASO decreased plasma cholesterol levels and improved NAFLD, with the downregulation of lipogenic genes, such as FASN, SREBP1 and stearoyl-coenzyme A desaturase 1 (SCD1). The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.